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Oral drug delivery has been the major route of drug delivery due to the ease of drug 
administration and patient compliance. Transdermal drug delivery is highly attractive 
for alternative drug delivery and yet faces significant challenges, largely due to the 
barrier function of the Stratum Corneum (SC) layer of the skin. Different chemical and 
physical methods have been explored to disrupt the SC layer to facilitate transdermal 
drug delivery. However, those methods only received limited successes due to the low 
efficiency in SC disruption or the potential safety risks.  
Ablative fractional laser (AFL) emerged in the last 2 decades as a novel technology 
for safe and efficient ablation of SC layer to facilitate transdermal drug delivery. AFL 
was fabricated based on the concept of fractional photothermolysis for improved skin 
resurfacing in cosmetic field. This technology emits tiny laser beams on skin surface 
to instantly increase skin temperature to over 100˚C and cause tissue evaporation. 
Because of this, tiny microchannels (MCs) are generated on skin surface to allow 
drugs to migrate into the skin with high efficiency. At the same time, the MCs can 
achieve quick and complete skin recovery in 2-3 days considering each of these MCs 
is surrounded by normal healthy skin with a good repairing capacity. AFL adequately 
addresses the dilemma about the safety and efficiency of SC ablation to facilitate 
transdermal drug delivery. The current dissertation focuses on developing novel 
delivery platforms for use in conjunction with AFL for extended drug release 
(Manuscript I and III) and transcutaneous vaccination (Manuscript II).  
In manuscript I, we coated ‘bulk’ amount of drug powder into reservoir patches and 
then topically applied onto AFL-treated skin to elicit multi-day sustained drug release. 
 
 
We found tapped coating could elicit 3-day sustained drug release, while compression 
coating could elicit 6-day sustained drug release. Drugs in gram scales can be 
potentially delivered via AFL-assisted reservoir patch delivery with compression 
coating. We further found such a delivery platform is suitable for the delivery of both 
small chemicals and macromolecules. 
In manuscript II, we coated vaccine powder on full-surface adhesive patches followed 
by topical application onto AFL-treated skin for transcutaneous vaccination. Beside 
delivery of vaccines alone, we found a clinical monophosphoryl lipid a (MPL) 
adjuvant could be encapsulated into poly(lactic-co-glycolic acid) (PLGA) 
nanoparticles (NPs) for delivery together with vaccines via the same delivery 
platform. AFL-assisted full-surface powder vaccine/MPL delivery induced much 
stronger vaccine-specific immune responses than vaccine delivery alone in both 
newborn and adult mice.  
In manuscript III, we embedded drugs into hydrogels for delivery via AFL-generated 
skin MCs. We found poly (vinyl alcohol) (PVA) hydrogel but not poly (2-
hydroxyethyl methacrylate) (pHEMA) hydrogel could serve as an efficient delivery 
platform to deliver drugs via AFL-generated skin MCs. AFL-assisted PVA hydrogel-
based zidovudine delivery was found to elicit almost 100% delivery efficiency and at 
the same time extend drug release to ~15 hours, while oral delivery only induced 
sustained release for up to 3 hours.  
AFL-assisted high-dose 6-day sustained powder drug delivery is promising to reduce 
dosing frequency and improve patient adherence in treatment of long-term chronic 
diseases. AFL-assisted hydrogel-based drug delivery provides another delivery 
 
 
platform for extended delivery of hydrophilic drugs. AFL-assisted full-surface 
vaccine/MPL delivery represents an innovative transcutaneous vaccination technology 
for needle-free delivery and adjuvantation of vaccine immunization. The needle-free 
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This dissertation has been written in the manuscript format according to the formatting 
guidelines of the target journal. It has been divided into three manuscripts that relate to 
reservoir patch-based powder drug delivery, full-surface powder vaccine delivery, and 
hydrogel-based transdermal drug delivery. The first manuscript examines AFL-
assisted high-dose powder drug delivery. This manuscript has been prepared following 
the Journal of Controlled Release guidelines. The second manuscript is focused on 
AFL-assisted full-surface powder vaccination in the presence of MPL adjuvant in both 
newborn and adult mice. This manuscript has been prepared following the Journal of 
Controlled Release guidelines. The final manuscript explores AFL-assisted hydrogel-
based transdermal drug delivery. This manuscript has been prepared following the 
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Transdermal delivery is highly attractive for alternative drug delivery due to its non-
invasiveness, self-administration, enhanced bioavailability and extended drug release. 
Current transdermal drug delivery is only limited to low-dose, small, hydrophobic 
drugs. In this study, we explored ablative fractional laser (AFL)-based powder 
reservoir patch for high-dose multi-day sustained delivery of hydrophilic drugs in 
murine models. This novel delivery platform is based on coating powder drugs into 
reservoir patches followed by topical application onto AFL-generated skin 
microchannels (MCs) to deliver drug into the skin. Using antiretroviral drug 
zidovudine (AZT) as a model hydrophilic drug, we found 11.42 mg AZT could be 
coated per 0.5 cm2 patch area with tapped coating to elicit 3-day sustained release, 
while ~68mg AZT could be coated per 0.5 cm2 patch area with compression coating to 
elicit 6-day sustained release. This study also explored microneedle (MN)-assisted 
powder reservoir patch delivery and we found AFL was more promising than MN to 
support more than 3-day sustained powder drug delivery. This can be attributed to the 
fact that AFL is more prone to generate relatively large skin MCs that remain open 
beyond 3 days. Besides small chemicals, AFL-based powder reservoir patch delivery 
could also be used for efficient delivery of macromolecules. 
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High-dose reservoir patches efficiently deliver powder drugs via ablative fractional 
laser-generated skin microchannels (MCs) over 6 days owing to water evaporation 




















Conventional oral dosage forms, like tablets and capsules, have been the first choice of 
drug delivery for decades due to the convenience of administration. However, most 
drugs administered by oral route have poor bioavailability due to hepatic first-pass 
effect and harsh conditions of the gastrointestinal tract [1]. 
Transdermal drug delivery is attractive due to the plethora of advantages it offers. It 
bypasses the hepatic metabolism, increases bioavailability, and can be self-applied. It 
might also lower drug dose and reduce dosing frequency. Yet only a few hydrophobic 
drugs can be delivered via transdermal route due to the barrier function of the stratum 
corneum (SC) layer [2-4]. SC layer is composed of specialized lipid structures that 
hinder the transmigration of large hydrophobic molecules and almost all hydrophilic 
molecules. The desirable attributes of drugs for transdermal drug delivery include a) 
molecular weight below 500 Daltons, b) specific log P coefficient, c) good oil and 
water solubility [5].  Different methods (e.g., chemical enhancers, iontophoresis, and 
ultrasound) have been explored to disrupt SC layer to facilitate transdermal drug 
delivery. Chemical enhancers modify lipid structures of the SC layer to increase drug 
permeation and yet can cause skin irritation due to the difficulty to limit their effects to 
the SC layer [2]. Iontophoresis uses electric fields to mobilize charged molecules 
across the SC layer and can conveniently control drug release rate by modulation of 
electrical current [2]. Iontophoresis is most effective to deliver small charged drugs. 
Ultrasound generates oscillating pressure waves at high frequencies (MHz) or 
cavitation bubbles at low frequencies (kHz) to disrupt SC layer to facilitate 




been found to be 3 orders of magnitude more effective than high-frequency 
sonophoresis (HFS) to increase transdermal drug delivery [6]. The safety and efficacy 
of LFS to enhance transdermal drug delivery remain to be explored in clinical settings.  
Lasers have also been explored to facilitate transdermal drug delivery. In early studies, 
laser beams of a few millimeters in diameter were used to ablate SC layer to facilitate 
transdermal drug delivery. The very first laser used for drug delivery was a pulsed 
argon fluoride excimer laser for SC ablation in 1987 [7]. Despite an effective strategy, 
full-surface laser ablation to facilitate transdermal drug delivery faces safety concerns 
due to delayed skin recovery. Recently, ablative fractional lasers (AFLs) have been 
fabricated for improved skin resurfacing with significantly shortened downturn time as 
compared to full-surface laser ablation. Due to complete ablation of SC layer, skin 
MCs have been found to greatly facilitate transdermal delivery of small chemicals, 
macromolecules, and nanoparticles with little restrictions on chemical structure, 
molecular weight, and particle size [8-12]. Due to the microscale size, skin MCs can 
be quickly and completely recovered in days [8-12]. The most widely used lasers for 
skin microporation include erbium-doped yttrium aluminium garnet (Er:YAG) laser, a 
portable Precise Laser Epidermal System (P.L.E.A.S.E), and carbon dioxide laser 
[13,14]. AFLs have been employed to study drug permeation that includes imiquimod, 
dextrans, 5-aminolevulinic acid [15-17].  
Recently, our group explored AFL-assisted powder drug delivery. Direct delivery of 
powders eliminates the need of reconstitution and may improve drug stability. In 
previous studies, powder drugs were coated in the same pattern as skin MCs on either 




delivery utilizes water absorption from skin MCs as a key component in powder drug 
delivery. It ablates a few hundred micrometers of skin layer (stratum corneum), which 
leads to trans-epidermal water loss. This water travels through the powder layers and 
dissolves it. Dissolved drugs then slowly diffuse into the skin via skin MCs. Surface 
coating was found to elicit quick drug delivery (~1 hr), while volumetric coating was 
found to elicit ~12 hour sustained drug release, leading to increased drug 
bioavailability in vivo [18,19]. Despite these advantages, current delivery platforms 
have relatively low coating and delivery capacity, comparable to traditional patches (a 
few milligrams a day) [20,21]. The majority of high-dose drugs cannot be delivered 
with these technologies. 
We explored high-dose powder drug delivery via AFL-generated skin MCs by coating 
powder drugs into reservoir patches. In this study, we report two types of reservoir 
patches to induce multi-day sustained drug release. The first type is based on tapped 
coating (40mg/0.5cm2) to induce 3-day sustained drug release and the second type is 









Materials and Methods 
Reagents 
Sulforhodamine B (SRB, 230161), mannitol (M4125), ovalbumin (OVA, A5503), 
texas red ovalbumin (TR-OVA) and zidovudine (AZT, A2169) were purchased from 
Sigma (St. Louis, MO). 3’-Azido-3’-deoxythymidine (AZT-IS, MG103), AZT internal 
standard, was purchased from Moravek Biochemicals (Brea, CA).  
Animals 
BALB/c mice (female, 6-8 weeks old) were purchased from Charles River 
Laboratories (Wilmington, MA). They were housed and maintained in the animal 
quarters of University of Rhode Island. For the experiments, the animals were 
anaesthetized for hair removal, laser and microneedle treatment, patch application and 
patch removal. Institutional Animal Care and Use Committees of URI approved all 
procedures. 
Generation of skin MCs 
An UltraPulse Fractional CO2 Laser from Lumenis Inc. (San Jose, CA) was used to 
generate skin MCs at laser energy (2.5, 5 and 10mJ) and skin coverage (5, 10, 20%). 
Stainless steel MNs with 56 MNs in ~1 cm circular area was kindly provided by Dr. 
Mark Prausnitz at Georgia Institute of Technology. Each MN was about 700µm in 
height, 200µm in width, and 50µm in thickness. MNs were pressed into mouse skin, 
waited for 10 seconds, and then retracted. MN application was repeated for multiple 
times and each time MN was turned clockwise for 5-10 degrees to avoid insertion into 





Patch preparation, coating and extraction 
For tapped coating, drug powder was loaded into plastic cylindrical container with 
8mm in diameter and 5mm in height and gently tapped. For compression coating, a 
centrifuge tube was filled with polydimethylsiloxane (PDMS) solution up to 70% and 
allowed to dry. A plastic reservoir patch was applied to the top layer of dries PDMS 
using an adhesive tape. Bulk drug powder was loaded over the plastic patch and was 
centrifuged at 20,000 rpm for 90 minutes. 
Patch application 
Hairless dorsal mouse skin was exposed to laser or MN treatment followed by topical 
application of the patches, which were then covered with a thin 3M Tegaderm. A 
bandage was applied to ensure that the patches stay in position till removal. 
Oral gavage 
Oral gavage of AZT was performed following a published protocol [22]. The mice 
were held vertically and a sterile plastic feeding tube was inserted and advanced into 
the stomach. The drug solution was slowly injected followed by careful removal of the 
tube from the stomach. 
LC-MS/MS quantification of AZT 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was employed to 
quantify blood AZT levels [23]. Patch extracts and AZT standards (6.25, 12.5, 25, 50, 
100, 200, 400 ng/ml) were mixed with 100 ng/ml AZT-Internal standard (IS) Serum 
samples were diluted 20 times, mixed with 100 ng/ml AZT-IS and filtered through 
10kDa cutoff Amicon filter purchased from EMD Millipore (Burlington, MA) 




Shimadzu LC-20AD pumps and a QTRAP 4500 System. A Synergi Hydro-RP 80A, 
2.0×150 mm, 4µm particle size analytical column (Phenomonex, Torrance, CA) was 
used for sample separation. Acquisition was performed in multiple reaction-
monitoring (MRM) mode using m/z 268/127 for AZT and 271/130 for AZT-IS 
detection. A standard curve was generated by plotting peak area ratios of AZT to 
AZT-IS against AZT concentrations and used to quantify AZT levels in the unknown 
samples. 
Statistical analysis 
All values were expressed as Mean ± SEM (standard error of mean). Student t-test was 
used to analyze the difference between mice groups. P value was calculated using 







Reservoir patch-based powder SRB delivery with tapped coating 
Considering some drugs have relatively high doses (tens to hundreds of milligrams), 
‘bulk’ drug powder was coated into reservoir patches for delivery via laser-generated 
skin MCs. Readily detectable SRB was used in this study. SRB has been reported to 
have a 50% lethal dose (LD50) of 887mg/kg in mice (i.e., 22mg SRB given to 25g 
mice will cause 50% death) [24]. To avoid potential toxicity, SRB was mixed with 
mannitol at 1:20 weight ratio and then lyophilized for reservoir patch coating and 
delivery. We found ~1.9mg SRB and ~38mg mannitol could be coated per reservoir 
patch and this SRB dose was not expected to pose any safety risks in mice. Powder 
SRB/mannitol-coated reservoir patches were topically applied onto laser-treated skin. 
Trans-epidermal water loss (TEWL) plays an important role in the delivery of powder 
drugs via laser-ablated skin MCs. We carried out drug delivery at 2.5mJ laser energy 
and different percentage coverages (5, 10, 20%) that vary in TEWL. As shown in 
Figure 1A, reservoir patches induced highly efficient SRB delivery and the delivery 
lasted for 1-3 days, depending on laser conditions. Delivery efficiency reached more 
than 90% within 24 hours in 20% laser coverage group, within 48 hours in 10% laser 
coverage group, and within 72 hours in 5% laser coverage group (Figure 1A), 
indicating a positive correlation between reservoir patch-based powder delivery and 
TEWL. This study supports modification of laser conditions to modulate duration of 
powder drug delivery via AFL-generated skin MCs. 
Skin images were taken right after patch removal at day 3. There were no local 




Besides efficient delivery, quick resealing of skin MCs at the end of delivery can 
minimize potential environmental pathogen infections. To explore the temporal MC 
resealing, we measured TEWL at different times after patch removal in 5% laser 
coverage group. As shown in Figure 1C, TEWL reduced from ~85 g/hm2 at the 
beginning of delivery to ~40 g/hm2 at the end of the 3-day delivery, hinting partial 
resealing of skin MCs during the 3-day period. After patch removal, TEWL reduced to 
baseline levels (~6 g/hm2) within 36 hours (Figure 1C), indicating complete resealing 
of skin MCs within this period. 
Reservoir patch images were also taken to explore kinetics of powder dissolution and 
delivery in 5% laser coverage group. SRB and mannitol were mixed at 1:50,000-
weight ratio for easy differentiation of dissolved from dry forms of SRB. As shown in 
Figure 1D, powder SRB/mannitol showed mainly mannitol color at the beginning of 
the delivery due to its dominant content and then pink color at 4 hours due to the 
absorption of evaporated water by intermixed SRB powder. With continuous water 
absorption and increase of moisture levels, SRB/mannitol powder changed to a wet 
mass at 12 hours (Figure 1D). The wet mass gradually reduced in volume and became 
complete liquid at 60 hours. Significant reduction of pink color of the liquid from 60 







Figure 1. Efficient reservoir patch-based powder SRB/mannitol delivery via laser-
generated skin MCs 
A. Lateral back skin of BALB/c mice was exposed to 2.5mJ laser treatment at 5%, 
10% or 20% coverage followed by topical application of powder SRB/mannitol-coated 
reservoir patches. Patches were removed at indicated times and delivery efficiency 
was then quantified. n=2-5. B. Skin images right after laser treatment of 2.5mJ/5% 
and post-patch removal at day 3. C. TEWL was measured before (Naïve skin) or right 
after laser (2.5mJ 5%) treatment, or at different times after patch removal on day 3. 
n=3. D. Powder SRB/mannitol-coated reservoir patches were topically applied onto 
laser (2.5mJ /5%)-treated skin. Patch pictures were taken at different times. 
Experiments were repeated 3 times and representative patch pictures were shown. 
Reservoir patch-based AZT delivery with tapped coating 
We found coating pure powder AZT into reservoir patches only achieved 4.6% 
delivery efficiency at the end of 2-day delivery (Figure 2). Thus, small sugar excipient 
mannitol was mixed with AZT at different ratios to explore whether it could enhance 




patches with tapped coating to calculate average loading (n=6) as shown in table 1. 
These patches contained 20 mg, 11.62 mg and 6.66 mg in 1:1, 1:2.5 and 1:5 mixing 
ratios, respectively.  Around 40 mg AZT/mannitol (Table 1) was found to be coated 
per reservoir patch with tapped coating. Laser energy of 5mJ and 5% skin coverage 
was used for all patch deliveries. An 8×8 mm2 area of female BALB/c mouse skin was 
exposed to laser treatment and the patch was then topically applied and secured in 
place. Serum AZT concentration was quantified using LC/MS/MS. Serum AZT levels 
peaked at around 16-20 hours and then slowly reduced to baseline levels in 3 days 
(Figure 3A-3C). Oral gavage delivery of 0.32 mg AZT was used for comparison. 
Serum AZT levels peaked at 30 minutes and declined to baseline within 3 hours of 
oral delivery (Figure 3D). The remaining AZT in laser-based patch delivery was 
quantified and compared with total coating amount to determine the delivery 
efficiency. We found approximately 51%, 93% and 90% delivery efficiency could be 
obtained at 1:1, 1:2.5 and 1:5 ratios, respectively (Figure 3E). A typical powder 
AZT/mannitol coated reservoir patch is shown in Figure 3F.  
 





Table 1. Tapped coating capacity at different AZT/Mannitol ratios. 
Ratio of AZT/Mannitol 
(weight:weight) 
Tapped coating capacity 
(Mean ± 
Standard deviation) (mg) 
AZT amount 
(mg) 
1:1 40.68 ± 3.29 20 
1:2.5 39.75 ± 3.55 11.42 






Figure 3. Efficient reservoir patch-coated powder AZT/mannitol delivery via laser 
generated skin MCs 
A-C. Lateral back skin of BALB/c mice was exposed to 5 mJ laser treatment at 5% 
followed by topical application of powder AZT/mannitol-coated reservoir patches at 
1:1 (A), 1:2.5 (B), and 1:5 ratios (C). Patches were removed at day 3 and delivery 
efficiency was then quantified. n=3 D. Oral gavage delivery of AZT solution in mice. 
n=3 E. Delivery efficiency of the three ratios. F. Close- view of AZT/mannitol-coated 
reservoir patch using tapped coating method at 1:2.5 mixing ratio. 
Reservoir patch-based powder AZT delivery with compression coating 
We next explored whether powder reservoir patches with compression coating could 
achieve high-efficient delivery and more extended drug release. Lateral back skin of 
mice was exposed to laser treatment (10 mJ and 5% skin coverage) followed by 
topical application of the reservoir patches with compression coating at 1:2.5 
AZT/mannitol ratio. Serum AZT levels were quantified as above. Similar patterns of 




4A). We also measured delivery efficiency by quantification and comparison of patch-
coated and remained AZT on day 6. We found approximately 94% AZT was delivered 
in 6 days. A typical powder reservoir patch following compression coating is shown in 
Figure 4B.  
  
Figure 4. Efficient reservoir patch-coated powder AZT/mannitol delivery via laser 
generated skin MCs 
A. Lateral back skin of BALB/c mice was exposed to 10 mJ laser treatment at 5% 
coverage followed by topical application of powder AZT/mannitol-coated reservoir 
patches (compression coating, 1:2.5 ratio). Patches were removed at day 6 and 
delivery efficiency was then quantified. n=3 B. Close-view of AZT/mannitol-coated 




Powder reservoir patch delivery via MN-generated skin MCs 
Besides laser, MNs use microscale needles to puncture the skin to create skin MCs, 
which have been also explored to facilitate transdermal drug delivery [10]. The ability 
of MN-generated skin MCs to facilitate reservoir patch-based powder delivery was 
also explored here. Stainless steel MNs as shown in Figure 5A were used to generate 
skin MCs. Due to crucial roles of water evaporation in transdermal powder delivery 
based on our previous experience, we first explored whether MN treatment could 
significantly increase TEWL value of the skin. We found quick retraction of MNs 
after insertion only slightly increased TEWL, while allowing MNs to stay in the skin 
for 10 seconds could significantly increase TEWL (data not shown). We found 10 MN 
applications could generate a similar TEWL to that generated by laser (2.5mJ 5%), 
while 3 and 6 MN applications generated lower TEWL values (Figure 5B). Powder 
SRB-coated reservoir patches (tapped coating) were topically applied onto the 
different MN-generated skin MCs. As shown in figure 5C, 10 MN applications 
achieved more than 85% delivery efficiency at 72 hours, while 3 and 6 MN 
applications induced less than 25% delivery efficiency within the same period. Skin 
images were taken right after 10 MN treatments and right after patch removal on day 
3. MN insertion sites were clearly visible, however MN-generated skin MCs were not 
visible by naked eye right after treatment (left, Figure 5D). Right after patch removal, 
signs of circular patch edges on skin were clearly visible and no other visible local 
reactions could be seen except slightly white-colored skin in patch-applied area (right, 






Figure 5. Efficient reservoir patch-coated powder SRB/mannitol delivery via MN-
generated skin MCs 
A. Pictures of stainless steel MNs used in this study. Each device contains 56 MNs in 
1-cm diameter circular area. B. TEWL of MN-treated skin after 3, 6, and 10 
applications. MNs were allowed to remain in the skin for 10 seconds before 
retraction. C. Powder SRB/mannitol-coated reservoir patches were topically applied 
on MN-treated skin. Patches were removed at different times and delivery efficiency 
was then quantified. n=3. D. Skin images right after 10 MN treatments and right after 
patch removal at day 3. E. TEWL before or right after 10 MN applications, or at 
different times after reservoir patch removal at day 3. n=3. 
The timelines of MC resealing were also explored. As shown in figure 5E, TEWL 
significantly reduced from ~84 g/hm2 at the beginning of delivery to ~20 g/hm2 at the 
end of the 3-day delivery in 10 MN applications group, hinting significant resealing of 




after patch removal in 10 MN applications group (Figure 5E). This study indicated 
that MNs could elicit similar delivery patterns if they induced similar levels of TEWL 
to laser ablation. 
Histological analysis of laser and MN-generated skin MCs 
The above studies indicated that both laser and MNs could be used to generate skin 
MCs to support efficient powder reservoir patch delivery. In our studies, similar 
delivery efficiencies (Figure 1A & 5C) were observed when laser and MNs generated 
similar TEWL (Figure 1C & 5E). Considering laser (2.5mJ 5%) generated 11×11 
array of skin MCs in 8×8 mm2 area, while 10 MN applications were estimated to 
create 560 skin MCs in a similar skin area assuming each MN application generated 
completely new skin MCs. The higher skin MC density in MN group hinted MN-
generated skin MCs might be smaller than laser-generated ones. To prove this, we 
conducted skin histological analysis of laser- and MN-generated skin MCs. Lateral 
back skin of mice was exposed to laser (2.5mJ/5%) or MN treatment (10 applications) 
and skin was dissected right after treatment, fixed in formalin and then subjected to 
paraffin sectioning and H&E staining (conducted at RI Hospital, Molecular pathology 
department). We found we could easily identify laser-generated skin MCs but not 
MN-generated skin MCs (Data not shown). To accurately compare the relative size of 
laser- and MN-generated skin MCs, full-surface powder SRB patches were topically 
applied onto laser- or MN-treated skin. Skin was dissected 60 minutes later and 
subjected to cryosectioning (RI hospital). With the help of readily detectable SRB, we 




were much bigger (Figure 6). This result explained quicker sealing of MN-generated 




Figure 6. Histological analysis of laser and MN-generated skin MCs 
A. Histology images of laser- and MN-treated mouse skin. B. Diameter of 
microchannels for laser and MN treated skin samples. Laser generated bigger 
microchannels in the skin compared to MN which explains the longer duration of drug 
delivery via skin MCs. n=6. 
Reservoir patch-based powder ovalbumin delivery with tapped coating 
Lastly, the potential of laser-based powder reservoir patch for high-dose 
macromolecule delivery was also explored. OVA with a molecular weight of ~43kDa 
was used as a model. We found that ~20 mg of lyophilized OVA could be coated into 
the reservoir patches with tapped coating. Powder OVA patches were then topically 
applied onto laser (2.5mJ/5%)-treated skin of mice. Patches were removed at different 
time points and patch-remained OVA was quantified by BCA assay. We found 38, 46 








Figure 7. Sustained bulk delivery of pure OVA 
20 mg of lyophilized ovalbumin was loaded in tapped coated reservoir patches and 
delivered using 2.5 mJ energy and 5% coverage. Delivery efficiency was measured at 







In this study, we explored powder-coated reservoir patches for high-dose drug 
delivery via AFL-generated skin MCs. Our previous studies explored volumetric 
coating of AZT to elicit 12-hour sustained release via AFL-generated skin MCs [19]. 
In this study, we found reservoir patch coating could significantly increase drug 
coating and delivery capacity and at the same time extend drug release to multiple 
days.  We found ~250 mg AZT/mannitol powder could be coated per reservoir patch 
with 0.5 cm2 surface area for efficient delivery via laser-generated skin MCs. It’s 
estimated that ~5 g drug powder equivalent to approximately 1.4 gram active drug 
based on current study of AZT can be coated into reservoir patches with 10 cm2 
surface area for efficient delivery via laser-generated skin MCs. Such a delivery 
capacity is expected to significantly expand drugs that can be delivered via 
transdermal route.  
Our current study confirmed importance of water evaporation in laser-assisted powder 
drug delivery. SRB imaging study (Figure 1D) discovered the dynamics of powder 
dissolution via laser-generated skin MCs. In more detail, entire powder gradually 
increased moisture levels, then transformed into a wet mass, and finally transformed 
into a liquid form. We also observed positive correlation between the duration of 
delivery and TEWL of the skin in both laser and MN-assisted powder deliveries 
(Figure 1A and 5C). MN-assisted powder SRB delivery indicated the presence of a 
threshold TEWL to enable high-efficient powder drug delivery as we found 3 and 6 
MN applications induced incomplete SRB delivery (Figure 5C). In the case of 




indicating the initiation of delivery from powder in close proximity to skin MCs. If 
TEWL is above the threshold levels, increase of laser energy or percent coverage is 
expected to increase the rate of drug delivery.  
AFL-based powder reservoir patch induced 3-phase drug release. In the first phase, 
relatively small amount of AZT (<5%) was delivered in 12-16 hours after patch 
application with relatively low serum AZT levels at 1:2.5 AZT:mannitol mixing ratios 
(Figure 3B and 4A). In the second phase, serum drug levels quickly increased to peak 
and then maintained at relatively high levels for 12 or 24 hours in case of tapped and 
compression coating, respectively (Figure 3B and 4A).  In the third phase, serum drug 
levels gradually reduced to baseline levels in the next 1.5 to 3 days (Figure 3B and 
4A). Such a delivery pattern follows first-order drug delivery and drug delivery rate 
was controlled by local drug concentrations. It remains to be explored whether more 
extended drug release could be elicited by increase of compression forces during patch 
coating. 
Our studies found AZT needed to be mixed with highly water-soluble mannitol to 
induce high-efficient delivery. AZT has a water solubility of ~25 mg/ml and mannitol 
has a water solubility of 216 mg/ml. Due to the slow water evaporation and the ‘bulk’ 
powder coating, drugs would have a very high concentration at the early stage of 
reservoir patch-based powder delivery. Assuming 40mg powder was completely 
dissolved in the reservoir patch with a calculated volume of 0.25ml, the drug 
concentration could reach 160mg/ml. Thus, dissolved drugs were saturated at the 
beginning of the delivery. The highly saturated drug concentration presents a 




highly water-soluble small sugar excipients to facilitate powder delivery. In addition, 
small sugar excipients are expected to have high diffusion efficiency due to their small 
molecular weight. In our study, we only tested mannitol to support high-efficient 
laser-based reservoir patch delivery. We believe other small sugar excipients and 
potentially amino acids can similarly enhance laser-based powder reservoir patch 
delivery.  
Our studies found MNs could also be used to generate skin MCs to support reservoir 
patch-based powder drug delivery. However, MN-generated skin MCs were much 
smaller than laser-generated skin MCs (Figure 6B). Thus, MN-generated skin MCs 
tended to more quickly reseal than laser-generated skin MCs (Figure 1C & 5E). The 
quick resealing of MN-generated skin MCs has been also observed by others and for 
this reason MNs have been mainly used to generate skin MCs to support short-term 
drug release [25,26]. It remains a challenge to use MNs to generate relatively big skin 
MCs considering big MNs greatly increase pain sensation [25]. As an alternative 
strategy, prolonging MC lifetime has been explored to support more extended (7-day) 
drug releases [27,28]. In our study, we found even the lowest laser condition could 
generate skin MCs that remained open beyond 3 days. Thus, laser may be a more 
promising technology to generate skin MCs to support 7-day or even longer sustained 
drug release. 
A small handheld laser device can be manufactured for convenient translation of this 
technology for high-dose multi-day sustained drug delivery in clinics. Multi-day 
sustained powder drug delivery is promising to reduce dosing frequency and improve 




reservoir powder patch delivery can also be painless. Powder reservoir patches require 
no reconstitution and may eliminate cold-chain storage for temperature-sensitive 
drugs. Powder reservoir patches also have a small package and storage volume. Laser-
based powder reservoir patch delivery warrants further investigation for advantageous 
transdermal drug delivery in humans.  
Conclusion 
In summary, we developed a high-dose drug delivery system by coating ‘bulk’ drug 
powder into reservoir patches followed by topical application onto AFL-generated 
skin MCs to initiate transdermal drug delivery. Coating methods can conveniently 
modulate the coating capacity and duration of delivery. Tapped coating can be 
employed for 3-day sustained drug delivery, whereas compression coating can be 
explored for 6-day sustained drug delivery. Laser-based powder reservoir patch 
delivery induces minimal local reactions and laser-generated skin MCs can be quickly 
resealed in 1-2 days after completion of the delivery.  Our study also supports laser as 
a more promising technology to generate skin MCs to support more than 3-day 
sustained drug release. Laser-based powder reservoir patch delivery involves no 
complex powder formulation and provides a convenient transdermal delivery platform 
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Needle injections have been the major method of vaccine delivery for a long time. Yet 
needle-based vaccination has the following drawbacks, like needle-phobia, needle-
stick injuries, and sharps wastes. Needle-free transdermal delivery is highly attractive 
for alternative vaccine delivery. Ablative fractional laser (AFL)-based full-surface 
powder vaccination was explored in this study for needle-free vaccine delivery and 
adjuvantation. In this platform, powder vaccines were coated onto full-surface 
adhesive patches followed by topical application onto laser-generated skin 
microchannels (MCs) to deliver vaccines into the skin. We found full surface-coated 
powder model antigen ovalbumin (OVA) and haemophilus influenzae type b (Hib) 
vaccine could be efficiently delivered via AFL-generated skin MCs and elicit 
comparable immune responses to needle-based subcutaneous delivery. To further 
boost vaccination, clinical lipophilic monophosphoryl lipid a (MPL) adjuvant was 
encapsulated into poly(lactic-co-glycolic acid) nanoparticles (NPs) and then coated 
together with OVA or Hib vaccine on full-surface adhesive patches for efficient 
delivery via AFL-generated skin MCs. AFL-assisted full-surface powder OVA and 
haemophilus influenzae type b (Hib) vaccine delivery in the presence of NP(MPL) 
elicited more than 70-fold higher anti-OVA and anti-Hib antibody titer than needle-
based subcutaneous delivery of OVA or Hib vaccine alone. AFL-assisted full-surface 
powder vaccination showed a good safety with minimal local reactions and quick skin 
MC resealing (1-2 days). The safe and highly immunogenic AFL-assisted full-surface 
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Full-surface powder patches efficiently deliver vaccines and monophosphoryl lipid a 
(MPL) adjuvant via ablative fractional laser-generated skin microchannels (MCs) to 
induce more potent immune responses than needle-based subcutaneous (SC) injection 



















The majority of vaccines are administered by intramuscular needle injections to induce 
immunological memory to protect against later infections [1]. Needle-based 
vaccination has the following disadvantages, such as pain, needle-stick injuries, 
generation of sharp waste and poor patient compliance, especially in children [2,3]. 
Pediatric patients are more prone to be anxious about getting a needle injection and it 
can lead to unwanted stress [4]. Intramuscular vaccine delivery often induces 
relatively weak immune responses due to the rare antigen-presenting cells (APCs) 
residing in the muscular tissue.  
There has been a recent interest in intradermal (ID) or transdermal vaccination due to 
the presence of a large number of APCs in the skin, such as epidermal Langerhans 
Cells (LCs) and various types of dermal dendritic cells (DCs) [5-8]. Modification of 
vaccine administration from IM to ID route by hypodermic needles was found to 
induce more potent immune responses against influenza vaccine, rabies vaccine, and 
hepatitis b vaccine [9-11]. Due to the thin skin tissue, hypodermic needle-based ID 
vaccination faces significant challenges to accurately deliver vaccines into the dermal 
tissue. To address this, ID adaptors and hollow microneedles (MicronJet600) were 
developed for use with traditional syringes for accurate ID vaccine delivery [12]. ID 
microinjection systems as a standalone ID delivery device with prefilled influenza 
vaccines have been also fabricated to save vaccine dose [13]. Needle-free Jet Injectors 
have been also developed for IM, subcutaneous (SC), or ID delivery depending on 
settings [14]. Besides ID delivery technologies, transdermal delivery technologies, like 




[15,16]. Dissolving microneedles were fabricated and tested in human volunteers in 
Phase 1 clinical trials with promising results generating similar or even higher immune 
responses compared to IM injections [17]. These innovative vaccine delivery 
technologies use ultra-fine and -short needles or completely eliminate needle use for 
more patient compliant vaccination. Most of these technologies were found to induce 
comparable immune responses to needle-based ID or IM delivery.  
Ablative fractional laser (AFL) has been also explored to facilitate transdermal 
vaccine delivery [18]. AFL is fabricated based on the concept of Fractional 
Photothermolysis, in which a focused array of laser beams generates skin MCs in the 
range of ten to hundred micrometers in diameter and depth [19]. These MCs have been 
found to facilitate transdermal delivery of macromolecules, including vaccines. Due to 
the sparing of majority of the skin from laser ablation, AFL causes minimal skin 
reactions and induces a fast recovery within 1-2 days [18,19]. In one study, an erbium-
doped yttrium aluminium garnet (Er:YAG) laser was employed to induce systemic 
antibody production [20]. In another study, a handheld Precise Lasers Epidermal 
System (P.L.E.A.S.E®) laser was used to generate skin MCs for allergy vaccine 
delivery in murine models [21].  
Due to the convenience of direct powder delivery, our group previously explored 
coating powder vaccines in the same pattern as Lumenis Ultrapulse CO2 laser-
generated skin MCs for transdermal vaccination [22]. We found delivery of highly 
reactive powder BCG vaccines into separated skin MCs induced minimal local 
reactions as compared to ID injection delivery [22]. Similarly, we found delivery of 




skin MCs also induced minimal reactions, while needle-based ID injection delivery 
induced significant local reactions, like erythema, swelling, and ulceration [22]. In 
these studies, microfractional BCG vaccine and OVA/LPS/CpG delivery via laser-
generated skin MCs were found to induce comparable immune responses to needle-
based ID delivery [22].  
In this study, we explored AFL to facilitate full-surface-coated powder vaccine 
delivery to avoid alignment between vaccine coating spots and skin MCs. This 
exploration was also inspired by our observation of the high potency of water 
evaporation from skin MCs to dissolve ‘bulk’ drug powder in reservoir patches in 
Chapter I. The water evaporation should be also able to dissolve full surface-coated 
vaccine powder to induce potent immune responses. This study also explored whether 
clinical monophosphoryl lipid A (MPL) adjuvant could be delivered via AFL-
generated skin MCs to boost vaccination. MPL, a nontoxic derivative of 
lipopolysaccharide (LPS), is a highly potent Toll-Like Receptor 4 (TLR4) agonist and 
an important component of combinatorial adjuvants, like AS04 (adsorption of MPL 
onto Alum adjuvant), or adjuvant systems, like AS01 (MPL and QS21 in liposome), 
and AS02 (MPL and QS21 in oil-in-water emulsion) [23]. AS04 adjuvant has been 
approved for incorporation into human papillomavirus (HPV) vaccine (Cervarix) and 
HBV vaccine (Fendrix) [24,25] and AS01 has been approved to boost malaria RTS,S 
vaccine efficacy [26]. Due to its relatively high molecular weight (synthetic MPL: 
~1763 Da), transdermal delivery of MPL has been challenging (unpublished data). 




MPL into poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) for delivery via 
AFL-generated skin MCs.  
We explored laser-based full-surface powder delivery (LPD) of OVA and 
haemophilus influenzae type b (Hib) vaccine in the presence or absence of 
nanoparticle-encapsulated MPL adjuvant in murine models. We found LPD of OVA 
and Hib vaccine in the presence of MPL adjuvant induced much higher immune 
responses than LPD or needle-based subcutaneous (SC) delivery of vaccine alone. 
LPD also induced minimal local reactions and quick skin MC resealing in 1-2 days. 





Materials and Methods 
 
Reagents 
Sulforhodamine B (SRB, 230161), ovalbumin (OVA, A5503), Texas Red-conjugated 
ovalbumin (TR-OVA), and poly(lactic-co-glycolic acid) (PLGA) polymer (719897, 
Resomer® RG 502 H, acid terminated, 7,000-17,000 Da), MPL (L6895), poly(vinyl 
alcohol) (PVA, P8136, 30,000-70,000 Da) were purchased from Sigma (St. Louis, 
MO). Hib vaccine (ActHIB®) was obtained from Sanofi Pasteur (Swiftwater, PA).  
Generation of skin MCs 
An UltraPulse Fractional CO2 Laser (Lumenis Inc. San Jose, CA) was used to generate 
skin MCs.  
Animals 
BALB/c and C57BL/6 mice (female, 6-8 weeks old) and hairless guinea pigs were 
purchased from Charles River Laboratories (Wilmington, MA). They were housed and 
maintained in the animal facilities of the University of Rhode Island (URI). Adult 
mice were anesthetized by intraperitoneal injection of Ketamine (80mg/kg) and 
Xylazine (10mg/kg) for hair removal, laser, patch application and transepidermal 
water loss (TEWL) measurement. Newborn C57BL/6 mice of both genders were self-
bred and used for Hib vaccine delivery when reaching one week old. Newborn mice 
were briefly anesthetized by intraperitoneal injection of Ketamine (15mg/kg) for laser 
treatment and patch application. All animal-related procedures were approved by the 





Lyophilized powder preparation 
OVA was mixed with mannitol at 1:25 weight ratio and then lyophilized in a benchtop 
freeze dry system (FREEZONE, Labconco). To prepare lyophilized OVA/NP(MPL) 
powder, OVA (62.5µg) was mixed with NP(MPL) (29.2mg) in water and then 
lyophilized. To prepare Hib/NP(MPL) lyophilized powder, Hib vaccine (12.5µg) 
dissolved in accompanying dissolving buffer was mixed with NP(MPL) (29.2mg) and 
then lyophilized. Due to the presence of salt, sucrose and other excipients in 
commercial lyophilized Hib vaccine and dissolving buffer, the lyophilized powder 
weighed ~41.7mg. 
Patch powder coating  
A 3M Tegaderm film was layered on top of a scotch packaging tape (3M) to form a 
sterile adhesive surface for powder coating. Patch adhesive layer was pressed onto 
‘bulk’ SRB or TR-OVA/OVA-mixed powder for an even full-surface coating. Patches 
were then cut into small pieces (3×3 mm2) for topical delivery in this study. For OVA 
vaccine delivery, lyophilized OVA/mannitol (1:25, weight/weight) powder was coated 
on adhesive patch surface as above and patches were cut into small pieces (3×3 mm2), 
each containing 2.5µg OVA determined by BCA protein assay kit after extraction in 
PBS. For OVA vaccine delivery in the presence of NP(MPL), about 1.17mg 
OVA/NP(MPL) powder that contained ~2.5µg OVA and 15µg MPL was weighed and 
coated on 3×3 mm2 adhesive patch surface by spreading with a spatula. For Hib 
vaccine delivery, Hib vaccine powder containing 0.5µg Hib vaccine was weighed and 




the presence of NP(MPL), about 1.67mg Hib/NP(MPL) that contained ~0.5µg Hib 
vaccine and 15µg MPL was weighed and coated on 3×3 mm2 adhesive patch surface.  
In vivo delivery 
Lateral back skin of adult or newborn mice were subjected to laser treatment to 
generate skin MCs followed by topical application of the above coated powder 
patches. Laser conditions used for OVA and Hib vaccination were 5mJ energy and 
10% coverage. Newborn mice were only explored for Hib vaccine delivery. Patches 
were covered with Tegaderm film to form an airtight system and further sealed in 
position with a narrow bandage without affecting free movement of mice. Patches 
were removed 2 days later in adult mice and 5 hours later in newborn mice. Newborn 
mice were kept on a digitally controlled heating pad at 37˚C during the 5-hour period 
and then returned to original cages. Immunization was repeated 2 weeks later. Serum 
anti-OVA or anti-Hib antibody titer was measured two weeks after boost. 
Serum antibody titer 
Small volume of blood (~20µl) was collected 2 weeks after boost. Serum anti-OVA or 
anti-Hib antibody titer was then measured by enzyme-linked immunosorbent assay 
(ELISA) by coating OVA (10µg/ml) or Hib vaccine (1µg/ml) into 96-well ELISA 
plates at 4°C overnight. After blocking in PBS supplemented in 5% non-fat milk, 
diluted serum samples were added and incubated at room temperature for 2 hours. 
After washing, anti-mouse IgG, peroxidase linked species specific whole antibody 
(from sheep) were added (1:2500) and plates were kept at room temperature for 1 
hour. After washing, TMB substrates were added and reactions were stopped by 2 M 





Patches were removed at different times and the remaining drugs were extracted into 
phosphate-balanced saline (PBS). Local skin surface was washed with PBS to recover 
undelivered drugs. Fluorescence intensity of SRB and TR-OVA in patch extracts 
before and after delivery, skin washes, and standard samples was measured at 
565/586nm and 596/615nm, respectively, in Spectramax M2 Multi-Mode microplate 
reader (Molecular Devices). Concentrations of SRB and TR-OVA were calculated 
based on standard curves. Delivery efficiency was then calculated based on the 
formula: (patch coating amount-patch remaining amount-skin surface amount)/patch 
coating amount × 100%. Drug amount on skin surface was found to be less than 1% in 
almost all deliveries (data not shown). 
PLGA NP preparation and characterization 
Single emulsion/solvent evaporation was used to prepare NP(SRB) and NP(MPL) 
[24]. In brief, 5mg SRB dissolved in 0.3ml dimethyl sulfoxide (DMSO) or 1mg MPL 
dissolved in 0.2ml chloroform was mixed with 80mg PLGA dissolved in 1.5ml 
dichloromethane (DCM). The mixture was added dropwise to 10ml 5% PVA solution 
while sonicating at 12 Watts for 2 minutes to form oil/water emulsion. Solvent was 
evaporated at room temperature with continuous stirring for at least 4 hours. NP(SRB) 
and NP(MPL) were then pelleted and washed with distilled water for 3 times followed 
by lyophilization. NP size was measured by Zetasizer Nano ZS90 (Malvern). To 
quantify encapsulated drug amount, ~1mg lyophilized NP(SRB) or NP(MPL) was 
weighed and hydrolyzed in 50µl 1N NaOH at 4˚C overnight followed by adjusting pH 




intensity at 565/586nm. MPL amount was quantified by stimulation of dendritic cells 
to release cytokines following a published protocol [25]. Near 100% encapsulation 
efficiency was observed for MPL (data not shown). 
Statistical analysis 
All values were expressed as Mean ± SEM (standard error of mean). Student t-test was 
used to analyze the difference between mice groups. P value was calculated using 











Efficient full-surface delivery of power SRB  
We first explored whether full-surface-coated powder could have a good delivery via 
AFL-generated skin MCs. Readily detectable fluorescence SRB was explored first. 
We found ~2.7 mg SRB could be coated per cm2 of the patch. Lateral back skin of 
mice was exposed to laser at different energies (2.5, 5, 10mJ) and percent coverages 
(5, 10, 20%) followed by topical application of powder SRB-coated patches onto 
laser-treated skin. As shown in figure 1A-1C, increase of laser energy and percent 
coverage increased powder SRB delivery. Delivery efficiency reached over 90% in 8 
hours for 2.5mJ laser conditions (Figure 1A), in 4 hours for 5mJ laser conditions 
(Figure 1B), and in 2 hours for 10mJ laser conditions (Figure 1C). 
 
Figure 1. Efficient full-surface powder SRB delivery via laser-generated skin MCs 
Female BALB/c mice were exposed to laser at different energies 2.5mJ (A), 5mJ (B), 
and 10mJ (C) and percent coverages (5, 10, 20%). Powder SRB-coated patches were 
then topically applied. Patches were removed at indicated times (1, 2, 4, 8, 18 hours) 





To better understand dynamics of powder SRB delivery, patch images were taken at 
different times in laser (5mJ/5%) group. Changes of SRB color from black in dry state 
to pink in wet state allowed us to explore temporospatial powder dissolution and 
delivery. As shown in figure 2, entire patch changed from black to dark pink color 1 
hour after patch application, hinting the absorption of evaporated water by entire SRB 
powder. At the same time, we observed an array of pink-colored spots, matching skin 
MCs, hinting active delivery of dissolved SRB powder via skin MCs. Significant 
water absorption and active delivery was consistent with over 40% delivery efficiency 
at this time (Figure 2). Patch changed to strong pink color at 2 hours and the pink 
color was then gradually reduced after 4 hours (Figure 2). Our data indicated that 




Figure 2. Imaging of SRB full-surface patch in vivo  
Powder SRB-coated patches were topically applied onto laser (5mJ 5%)-treated skin 
of BALB/c mice. Patch images were taken at different times. Experiments were 
repeated 3 times and representative patch images were shown. Arrows point to an 
array of pink colored spots matching skin MCs. Scale: 667µm. 
 
Due to the importance of water evaporation in AFL-assisted powder delivery, we 




found laser ablation significantly increased TEWL of the skin even at the lowest laser 
condition (Figure 3A). Increase of laser energy or percent coverage accordingly 
increased TEWL (Figure 3A). Interestingly, we observed highly positive correlation 
between 1-hour delivery efficiency and TEWL (Figure 3B). 
 
 
Figure 3. TEWL and correlation with powder SRB delivery efficiency  
A. TEWL of laser-treated or non-treated control skin. n=3. B. Correlation analysis 
between 1-hour delivery efficiency and TEWL (9 data points). 
 
Efficient full-surface delivery of powder OVA 
Next we explored whether full-surface-coated powder model antigen ovalbumin 
(OVA) could be efficiently delivered via AFL-generated skin MCs. To facilitate 
detection, TR-OVA was mixed with OVA in a 1:8 weight ratio and then lyophilized 
and coated on full-surface of adhesive patches. We found ~0.64 mg OVA could be 
coated per cm2 of the patch. Delivery efficiency was explored by quantification and 
comparison of fluorescence intensity of patch-remained and total coated TR-OVA. As 
shown in figure 4A-4C, increase of laser energy and percent coverage was found to 
increase the rate of OVA delivery. Delivery efficiency reached more than 80% in 4 




observed highly positive correlation between 1-hour delivery efficiency of OVA and 
TEWL (Figure 4D). This study hinted that full-surface-coated model antigen OVA 
could be efficiently delivered via laser-generated skin MCs.  
  
 
Figure 4. Efficient full-surface powder OVA delivery via laser-generated skin MCs 
A-C. Lateral back of BALB/c mice was exposed to laser followed by topical 
application of powder OVA-coated patches onto laser-treated skin. Patches were 
removed at different times (1, 4, 8, 18 hours) and delivery efficiency was then 
quantified. n=2-4. D. Correlation analysis between 1-hour delivery efficiency and 
TEWL (9 data points). 
 
Efficient full-surface delivery of powder PLGA NPs 
To evaluate whether full-surface-coated powder PLGA NPs could be efficiently 
delivered via laser-generated skin MCs, SRB was encapsulated into PLGA NPs to 




likely to affect delivery efficiency. NP (SRB) was found to have a size of 254 nm with 
a polydispersity index (PDI) of 0.103 (Figure 5).  
 
Figure 5. Size of NP(SRB) measured by Zetasizer Nano ZS90 (Malvern) 
 
Lyophilized NP(SRB) (with approximately 1% encapsulation efficiency of SRB) was 
then coated on adhesive patch surface and topically applied onto laser (5mJ, 
5/10/20%)-treated skin of BALB/c mice. Delivery efficiency was measured 48 hours 
later.  
 
Figure 6. Efficient full-surface delivery of powder PLGA NPs 
Lateral back skin of mice was exposed to AFL treatment at 5mJ energy and 5/10/20% 




patches. Patches were removed at indicated times (1,4, 8, 24, 48 hours) and delivery 
efficiency was quantified. n=3. 
 
As shown in Figure 6, more than 80% NP(SRB) was delivered into laser-treated skin 
within 4 hours, indicating AFL-assisted full-surface powder delivery could also 
efficiently deliver PLGA NPs. This study supported encapsulation of MPL into PLGA 
NPs for efficient delivery via laser-generated skin MCs. 
Laser-assisted full-surface powder OVA vaccination in the presence and absence 
of NP(MPL) 
Next we explored laser-assisted powder OVA immunization in the presence or 
absence of NP(MPL). NP(MPL) was found to have a size of 310 nm with a PDI of 
0.264 (Figure 7). We also compared relative potency of laser-assisted powder delivery 
with needle-based SC delivery. The reason to choose SC delivery rather than ID 
delivery was to avoid significant local reactions following ID NP(MPL) delivery (data 
not shown). Powder OVA-coated patches with or without NP(MPL) were topically 
applied onto laser (5mJ/10%)-treated skin of C57BL/6 mice in laser-based powder 
delivery (LPD). For comparison, the same dose of OVA or OVA/NP(MPL) were 
injected subcutaneously. Immunization was repeated 2 weeks later and serum anti-
OVA antibody titer was measured 2 weeks after prime and boost. Serum anti-OVA 
antibody titer after prime immunization was below 20 in OVA immunization alone 
groups and incorporation of NP(MPL) was found to increase serum anti-OVA 
antibody titer to 4000 in LPD group and 3400 in SC group (Left, Figure 8). After 
boost immunization, serum anti-OVA antibody titer increased to 300 in LPD of OVA 




Incorporation of NP(MPL) was found to increase serum antibody titer to 83,510 in 
LPD and 14,270 in SC delivery, respectively (Right, Figure 8), corresponding to 
~280-fold increase in LPD and 65-fold increase in SC delivery. Considering local 
reactions are a big concern for incorporation of adjuvants into ID or transdermal 
vaccinations, we further explored local safety of LPD of OVA in the presence of 
NP(MPL). As shown in Figure 9, minimal local reactions could be found in LPD of 
OVA alone and skin completely recovered in 1-2 days. Slight local reactions, like skin 
redness, could be found in LPD of OVA/NP(MPL) right after patch removal and skin 
completely recovered in 3 days (Figure 9). The most immunogenic LPD in the 
presence of NP(MPL) with good local safety supported further exploration of this 
technology for real vaccine delivery.  
 
 






Figure 8. Comparison of laser-based powder OVA delivery with subcutaneous (SC) 
delivery in the presence and absence of NP(MPL) 
Powder OVA vaccine-coated patches with or without NP(MPL) were topically applied 
onto laser (5mJ/10%)-treated skin of C57BL/6 mice. In other group, same dose of 
OVA or OVA/NP(MPL) were injected subcutaneously. Patches were removed 48 
hours later. Immunizations were repeated two weeks later and serum anti-OVA 









Lateral back skin of mice was exposed to laser (5mJ/10%) followed by topical 
application of powder OVA-coated patches (3×3 mm2) or powder OVA/NP(MPL) 
patches (5×5mm2). Skin images were taken right after patch removal and daily for 3 
days after patch removal to explore local reactions in the presence or absence of 
NP(MPL) adjuvant. Scale: 1mm. 
 
Laser-assisted full-surface powder Hib vaccination in the presence or absence of 
NP(MPL) in newborn and adult mice 
Hib vaccines are currently given to infants 3 times within the first 6 months of life by 
needle injection to protect serious illnesses caused by the bacteria Haemophilus 
Influenzae. The needle-free and potentially painless LPD may provide a better 
immunization strategy for newborns. In addition, incorporation of MPL adjuvant may 
improve Hib vaccine immunogenicity. To explore this, powder Hib vaccine-coated 
patches in the presence or absence of NP(MPL) were topically applied onto laser 
(5mJ/10%)-treated skin of newborn and adult mice. Immunization was repeated 2 
weeks later. As shown in figure 10A, LPD and SC delivery of Hib vaccine alone in 
newborn mice induced weak immune responses with serum anti-Hib vaccine antibody 
titer below 100. Simultaneous delivery of NP(MPL) in newborn mice significantly 
increased serum anti-Hib vaccine antibody titer to 2,520 in SC group and 1,810 in 
LPD group (Figure 10A). Due to the mature immune system, the same immunization 
induced much higher anti-Hib vaccine antibody titer in adult mice. As shown in figure 
10B, Hib vaccination alone induced serum anti-Hib vaccine antibody titer of 200 and 




antibody titer to 17,630 and 11,310 in SC and LPD group, respectively (Figure 10B), 
corresponding to 88- and 15-fold increase, respectively. These results validated LPD 
for Hib vaccine delivery and the effectiveness of NP(MPL) to boost Hib vaccination in 
newborn and adult mice. 
 
Figure 10. Comparison of laser-based powder Hib vaccine delivery with SC delivery 
in the presence or absence of NP(MPL) 
Powder Hib vaccine-coated patches with or without NP(MPL) were topically applied 
onto laser (5mJ/10%)-treated skin of C57BL/6 mice. In SC group, the same dose of 
Hib vaccine with or without NP(MPL) were subcutaneously injected in newborn (A) 
and adult mice (B). Patches were removed 48 hours later. Immunizations were 
repeated two weeks later and serum anti-Hib vaccine antibody titer was measured 2 
weeks after prime and boost. n=2 in newborn mice 4 in adult mice.  
 
 
Efficient full-surface powder OVA delivery in guinea pigs 
Due to the thin mouse skin, laser-assisted full-surface powder delivery was further 




[27]. As in mouse study, TR-OVA was mixed with OVA at 1:8 ratio and then 
lyophilized and coated on full-surface adhesive patch surface and then topically 
applied onto laser-treated skin of guinea pigs. We found the same laser condition 
generated lower TEWL in guinea pig skin (Figure 11) as compared to mouse skin 
(Figure 3A).   
 
 
Figure 11. TEWL of laser-treated guinea pig skin 
Hairless guinea pigs were treated with laser at different combinations of laser energy 
(2.5, 5, 10mJ) and percent coverage (5, 10, 20%). TEWL of intact skin and laser-
treated skin was measured right after treatment. n=3. 
 
Therefore, two pulses of laser at relatively high laser energies (10 and 20mJ) and 10% 
coverage were used to treat skin to generate skin MCs to explore the delivery 
efficiency in guinea pigs. Patches were removed 24 hours later and as shown in Figure 
12, both laser conditions elicited almost complete delivery of TR-OVA/OVA mixture. 
This study indicated that laser-based full-surface powder vaccination was also 







Figure 12. Efficient delivery of powder OVA in guinea pigs 
Lateral back skin of hairless guinea pigs was exposed to laser at indicated conditions 
followed by topical application of powder TR-OVA/OVA-coated patches onto laser-
treated skin. Patches were removed at 24 hours and delivery efficiency was then 







This study explored laser-based full-surface powder delivery (LPD) for needle-free 
transdermal vaccination. LPD is based on coating powder vaccines on full-surface 
adhesive patches followed by topical application powder vaccine-coated patches onto 
laser-generated skin MCs to deliver vaccines into the skin. We found full surface-
coated powder SRB, model antigen OVA, and PLGA NPs could be efficiently 
delivered into the skin via laser-generated MCs in murine models. More than 80% 
delivery efficiency of SRB, OVA, and NP(SRB) could be achieved within 4 hours 
(Figure 1A-1C, 4A-4C & 6). Our studies indicated that water evaporated from skin 
MCs was highly competent to dissolve full surface-coated small chemicals and 
macromolecules and elicit high-efficient delivery via laser-generated skin MCs. 
Remarkably PLGA NPs could also achieve high-efficient delivery via laser-generated 
skin MCs. We also found crucial roles of water evaporation in laser-based full-surface 
powder vaccination as supported by a highly positive correlation between early-stage 
delivery efficiency and TEWL value of the skin (Figure 3B & 4D).  
LPD of OVA was found to induce comparable immune responses to SC delivery 
(Figure 8). Incorporation of NP(MPL) was found to significantly boost OVA 
immunization in both deliveries (Figure 8). LPD of OVA in the presence of NP(MPL) 
induced ~6 times higher anti-OVA antibody titer than SC delivery (Figure 8). LPD of 
OVA in the presence of NP(MPL) induced minimal local reactions (Figure 9). This is 
very important considering SC or transdermal delivery of vaccine alone was found to 




which hampers the incorporation of external adjuvants to further boost ID or 
transdermal vaccination.  
LPD of Hib vaccine was found to also induce comparable immune responses to SC 
delivery in adult mice (Figure 10B). Incorporation of NP(MPL) was found to further 
boost Hib vaccination in both deliveries (Figure 10B). Besides significantly boosting 
vaccination, no significant difference of anti-Hib vaccine antibody titer could be found 
between LPD and SC groups in adult mice. In newborn mice, LPD of Hib vaccine also 
induced comparable immune responses to SC delivery (Figure 10A). Furthermore, co-
delivery of NP(MPL) also significantly increased anti-Hib vaccine antibody titer in 
newborn mice (Figure 10A). Our studies validated LPD for transdermal vaccine 
delivery and NP(MPL) as a highly potent adjuvant to further boost vaccination. In 
these studies, we observed weaker immune responses induced in newborn mice as 
compared to adult mice, which can be explained by the immature immune system of 
newborn mice [30]. To our knowledge, this study represented one of the two studies 
that successfully delivered MPL via the transdermal route. In the other study, MPL 
was formulated with trehalose into particulate form for ID ballistic delivery by 
PowderJect [31]. In PowderJect delivery, vaccines needed to be formulated with heavy 
metals for successful deposition into the skin. LPD involves no complex powder 
formulation and can efficiently deliver vaccine into the skin with ease. Our study also 
found high efficient delivery of full surface-coated powder OVA via laser-treated skin 
in guinea pigs. This study supports the potential application of laser-based full-surface 
powder vaccination in humans. Direct powder vaccination might also eliminate cold-





In summary, we developed laser-based full-surface powder delivery as an innovative 
delivery platform for transdermal vaccination. Laser-based full-surface powder 
vaccine delivery could elicit comparable immune responses to needle-based SC 
delivery. Such a delivery platform could also efficiently deliver NP(MPL) and co-
delivery of NP(MPL) was found to profoundly boost OVA and Hib vaccination in 
both newborn and adult mice. Laser-based full-surface powder vaccination in the 
presence of NP(MPL) also induced mild local reactions and laser-treated skin could 
recover within 3 days. Laser-based full-surface powder delivery was found to also 
efficiently deliver OVA in guinea pigs with a similar skin to human skin. The safe and 
highly immunogenic laser-based full-surface powder vaccination warrants further 
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Transdermal delivery is highly attractive for alternative drug delivery and yet is 
hampered by the barrier function of the stratum corneum (SC) layer of the skin. 
Ablative fractional laser (AFL) provides a safe and efficient approach to ablate SC 
layer to facilitate transdermal drug delivery. Different dosage forms like liquids, 
cream, lotion, and powder have been found to efficiently deliver via AFL-generated 
skin microchannels (MCs). Hydrogel-mediated drug delivery has recently received 
extensive attention due to its porosity, biocompatibility, and biodegradability. This 
study explored whether hydrophilic drugs could be encapsulated into hydrogels for 
efficient delivery via AFL-generated skin MCs. We found poly (vinyl alcohol) (PVA) 
but not poly 2-Hydroxyethyl methacrylate (pHEMA) hydrogels to elicit sustained 






















Oral drug delivery often requires frequent dosing or high drug amounts to achieve 
therapeutic effects. This can lead to poor patient compliance and drug toxicity [1, 2]. 
Oral delivery also leads to poor bioavailability of certain drugs due to extensive 
degradation and metabolism in the gastrointestinal systems. Transdermal delivery is 
highly attractive for alternative drug delivery and is yet hampered by the barrier 
function of the stratum corneum (SC) layer of the skin [3, 4]. 
Ablative fractional laser (AFL) has been explored as a safe and efficient approach to 
ablate SC layer to facilitate transdermal drug delivery in different dosage forms [5]. In 
one study, successful permeation of diclofenac in solution form was achieved in 
excised porcine and human skin using a portable AFL named Precise Lasers 
Epidermal System (P.L.E.A.S.E.®) [6]. In another study, a topical terbinafine 
antifungal cream was administered to patients with onychomycosis with a carbon-
dioxide AFL [7]. In our previous studies, we efficiently delivered powdered AZT via 
AFL-generated skin microchannels (MCs) over a span of 15 hours with a 100% 
bioavailability enhancement as compared to oral delivery in mouse models [8]. 
Hydrogels are 3-dimensional cross-linked water-soluble polymer networks and can be 
prepared in different physical forms, like slabs, films, and coatings. Hydrogels are 
highly biocompatible and biodegradable and drugs can be loaded into the gel matrix 
for slow diffusion out of the gel. Hydrogels can also be developed to respond to 
external stimuli to release drugs. Hydrogels can also adapt to the shape of the 




drug delivery systems.  Hydrogels also have tunable mechanical strength based on 
concentration of polymers [9].  
Hydrogel drug delivery systems have been developed for controlled drug release. 
Hydrogels can be prepared from synthetic polymers such as poly (vinyl alcohol) 
(PVA) [10], or natural polymers such as alginate [11], collagen [12] and chitosan [13]. 
In situ gelling hydrogels are injected in liquid form and follow a sol-gel transition in 
the body. Insulin release was observed over two weeks in an in situ gelling hydrogel in 
mice [14]. In other cases, hydrogels need to be surgically implanted, which limits its 
routine practice in drug delivery applications [15-17].  
Here we explored whether topical application of drug-loaded poly 2-Hydroxyethyl 
methacrylate (pHEMA) and PVA hydrogels onto AFL-treated skin could elicit high-
efficient drug delivery in murine models. We found PVA but not pHEMA hydrogel 
systems elicited efficient and sustained SRB and AZT delivery via AFL-generated 




Materials and methods 
 
Reagents 
Sulforhodamine B (SRB, 230161), poly(vinyl alcohol) (PVA, 563900, 1,30,000 Da), 
2-2’-Azobis(2-methylpropionitrile) (AIBN,441090), dichloromethylsilane (440248) 
and zidovudine (AZT, A2169) were purchased from Sigma (St. Louis, MO). 3’-Azido-
3’-deoxythymidine (AZT-IS, MG103), AZT internal standard, was purchased from 
Moravek Biochemicals (Brea, CA). Ethylene dimethacrylate (EGDMA, 409922500), 
2-Hydroxyethyl methacrylate (HEMA, 156335000) and N-Vinyl-2-pyrrolidone (NVP, 
140925000) were purchased from Acros Organics. 
pHEMA hydrogel preparation 
pHEMA hydrogels were prepared as per a published protocol [18]. In brief, 0.089 g 
Vinyl-2-pyrrolidone (VP) as co-monomer and 0.127 g Ethylene dimethacrylate 
(EGDMA) as a cross-linker was added to 8 ml 2-Hydroxyethyl methacrylate (HEMA) 
(monomer) followed by the addition of the initiator 2-2’-Azobis(2-
methylpropionitrile) (AIBN) (0.013 g) and continuous stirring until a clear solution 
was obtained. This solution was poured between dichloromethylsilane-treated glass 
plates and incubated at 50°C for 12 hours followed by 70°C for 24 hours. The plates 
were then removed and immersed in distilled water until the hydrogel separated. The 
hydrogel was then immersed in distilled water for one week to remove unreacted 
monomers. Water was changed once a day. 
SRB loading was carried out by immersing the hydrogels in 50mg/ml solution of SRB 





PVA hydrogel preparation 
PVA hydrogels were prepared by 5% w/v high molecular weight PVA in water. 
Freeze thaw method was used to prepare hydrogels. Drugs were loaded into the 
polymer solution and stirred for 5 hours. The solution was then transferred to plastic 
petri dishes and freeze-thawed for 3 cycles. Each freezing cycle was 2 hours at -20°C 
followed by thawing for 1 hour at room temperature. The obtained hydrogels were cut 
to required size, sealed in plastic bags and stored at 4°C until further use. 
Animals 
BALB/c mice (female, 6-8 weeks old) were purchased from Charles River 
Laboratories (Wilmington, MA). They were housed and maintained in the animal 
quarters of University of Rhode Island. For the experiments, the animals were 
anaesthetized for hair removal, laser treatment, patch application and patch removal. 
For in vitro study, mice were euthanized after laser treatment with CO2 and skin was 
dissected. Institutional Animal Care and Use Committees of URI approved all 
procedures. 
Generation of skin MCs 
An UltraPulse Fractional CO2 Laser purchased from Lumenis Inc. (San Jose, CA) was 
used to generate skin MCs.  
Patch application 
Hairless dorsal mouse skin was exposed to laser treatment followed by careful 
placement of the patches and then a thin 3M Tegaderm membrane to completely cover 




contact with the skin. A bandage was applied over the delivery area to ensure that the 
patches stay in position till removal. 
Delivery efficiency and patch extraction 
Patches were removed at different times and the remaining drugs were extracted into 
phosphate-balanced saline (PBS). The patches were immersed in PBS for 7 days and 
agitated on a vortex several times a day to expedite the release of remaining drugs. 
Local skin surface was washed with PBS to recover undelivered drugs. Fluorescence 
intensity of SRB in patch extracts before and after delivery, skin washes, and standard 
samples were measured at 565/586nm, in Spectramax M2 Multi-Mode microplate 
reader (Molecular Devices). Concentrations of SRB were calculated based on standard 
curves. Delivery efficiency was then calculated based on the formula: (patch coating 
amount-patch remaining amount-skin surface amount)/patch coating amount × 100%. 
AZT concentrations were measured using LC-MS/MS as described in later section. 
Franz cell studies 
Franz cell system with orifice diameter of 5 mm and recipient chamber volume of 1.5 
ml were custom made by Permegear. Patches were applied to laser treated skin and 
excised. It was then mounted on top of the recipient chamber and secured in place by a 
3 M tegaderm membrane. Donor chamber was placed above this and both the 
chambers were clamped. 1.5 ml PBS was added to the recipient chamber and a small 
stir bar ensured continuous stirring of the solution. 100 µl samples were collected at 
various time points and replenished with an equal volume of fresh PBS. The Franz 





LC-MS/MS quantification of AZT 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was employed to 
quantify blood AZT levels [19]. Patch extracts and AZT standards (6.25,12.5, 25, 50, 
100, 200, 400 ng/ml) were mixed with 100 ng/ml AZT-Internal standard (IS) Serum 
samples were diluted 20 times, mixed with 100 ng/ml AZT-IS and filtered through 
10kDa cutoff Amicon filter purchased from EMD Millipore (Burlington, MA) 
Samples were loaded into an AB Sciex 4500 QTRAP LC-MS/MS equipped with 
Shimadzu LC-20AD pumps and a QTRAP 4500 System. A Synergi Hydro-RP 80A, 
2.0×150 mm, 4µm particle size analytical column (Phenomonex, Torrance, CA) was 
used for sample separation. Acquisition was performed in multiple reaction-
monitoring (MRM) mode using m/z 268/127 for AZT and 271/130 for AZT-IS 
detection. A standard curve was generated by plotting peak area ratios of AZT to 
AZT-IS against AZT concentrations and used to quantify AZT levels in the unknown 
samples. 
Statistical analysis 
All values were expressed as Mean ± SEM (standard error of mean). Student t-test was 
used to analyze the difference between mice groups. P value was calculated using 






In vitro SRB delivery via pHEMA hydrogel 
Pre-cut hydrogels were immersed in a 50mg/ml solution of SRB for 5 days. We found 
225 µg SRB could be loaded in a 4×4 mm2 patch with 1mm thickness. Lateral back 
skin of mice was exposed to laser (5mJ/5%) followed by dissection and mounting onto 
the recipient chamber of the Franz diffusion cell. SRB-incorporated hydrogels of 4×4 
mm2 in size were then topically applied and secured with a 3M tegaderm membrane. 
100 µl samples were collected at multiple intervals for 30 days and replenished with 
100 µl fresh PBS. 
SRB amount in harvested samples and patches were analyzed 30 days after delivery. 
We observed a linear delivery of SRB in the first 15 days followed by cessation of 
delivery in the next 15 days (Figure 1A). Delivery efficiency reached about 60% at 
day 30 (Figure 1B).  
Figure 1. pHEMA hydrogel-based in vitro SRB delivery  
A. Delivery kinetics of SRB. Dissected skin of BALB/c mice was exposed to 5mJ laser 




patches. B. Patches were removed at day 30 and delivery efficiency was then 
quantified. n=3. 
pHEMA hydrogel-based in vivo SRB delivery  
Similar SRB patches were topically applied onto laser-treated mouse skin to study 
SRB delivery in vivo. We did not observe any change in color even at day 7 (Figure 
2). We then removed hydrogel and found it completely dried, which could be the 
reason of inefficient delivery considering SRB could only diffuse out of hydrogel and 
through laser-generated skin MCs in an aqueous environment.  
 
Figure 2. pHEMA hydrogel-based in vivo SRB delivery  
Lateral back skin of BALB/c mice was exposed to 5mJ laser treatment at 5% coverage 
followed by topical application of contact lens hydrogel patches. Patch images were 








PVA hydrogel-based in vitro SRB delivery 
We then explored a water-rich PVA hydrogels for AFL-assisted drug delivery. To this 
end, we added SRB into 5% w/v PVA solution followed by freeze-thaw cycles to yield 
relatively ‘moist’ hydrogels. A typical PVA-SRB patch is shown in figure 3. SRB 
loading amount was measured by extracting SRB from the hydrogel in PBS for 7 days 
with agitation on a regular basis until an almost clear hydrogel was visible. 1.8 mg of 
SRB was loaded into 4×4 mm2 patches with a thickness of 1.5 mm as shown in figure 
3. Hairless mouse skin was dissected after laser treatment at 5mJ/5%. The skin was 
placed on top of the receptor compartment of a Franz diffusion cell and secured with a 
3M tegaderm film after patch application. The receptor compartment was filled with 
1.5 ml of PBS and 100 µl samples were collected at different time points up to 10 
days. As shown in Figure 4A, SRB permeation rose to around 150 µg/ml at day 10. 
Delivery efficiency was calculated for all the patches as shown in figure 4B. 
Figure 4. PVA hydrogel-based in vitro SRB delivery 
A. Dissected skin of BALB/c mice was exposed to 5mJ laser treatment at 5% coverage 
followed by topical application of PVA hydrogel patches containing SRB. Delivery 
kinetics were measured in comparison to untreated skin. B. Patches were removed day 




PVA hydrogel-based in vivo SRB delivery 
Next we explored whether laser-based PVA hydrogel could achieve high-efficient 
delivery of SRB in vivo. Mouse skin was treated with 10mJ/10 % laser in a 4×4 mm2 
area. SRB patches with 2.8 mg loading were used for this study. Patches were 
removed after 3 days when the color intensity of SRB looked faint by visual 
observation. The patches were extracted in PBS for seven days to quantify remaining 
SRB amount. Delivery efficiency was found to be approximately 99% at the end of the 
3-day period (Figure 5).  
 
 
Figure 5. PVA hydrogel-based in vivo SRB delivery 
Lateral back skin of BALB/c mice was exposed to 10mJ laser treatment at 10% 
coverage followed by topical application of PVA-SRB hydrogel patches with 2.8 mg 
SRB. Patches were removed day 3 and delivery efficiency was then quantified. n=4.  
PVA hydrogel-based in vivo SRB delivery at increased doses 
To test delivery capacity of the hydrogel system, we incorporated a higher dose of 




and thickness remained same as in previous studies. Drug loading per patch was 
increased to 6.9 mg. We used the same laser condition of 10mJ/10% to observe the 
efficacy of delivery. Similar delivery efficiency of 99% was observed at the end of 3 
days (Figure 6). 
 
Figure 6. In vivo delivery of PVA-SRB hydrogels 
Lateral back skin of BALB/c mice was exposed to 10mJ laser treatment at 10% 
coverage followed by topical application of PVA-SRB hydrogel patches with 6.9 mg 
SRB. Patches were removed 3 days later and delivery efficiency was then quantified. 
n=4.  
PVA hydrogel-based in vivo AZT delivery 
We found coating SRB into PVA hydrogels achieved more than 99% delivery 
efficiency at the end of 3 days. Considering this, we explored the delivery efficiency 
and kinetics of a real drug AZT. Approximately 1.8 mg of drug was loaded into a 5×5 
mm2 patch with a thickness of 2 mm. A typical AZT hydrogel patch following freeze 
thaw cycle (before cutting into smaller patches) is shown in figure 7. Mouse skin was 




female BALB/c mice was treated with laser and the patch was secured in place with a 
3M tegaderm film and covered with bandage to prevent patch removal. Approximately 
30 µl of blood was collected at various time points and serum was separated and 
stored in -80°C until quantification.  
AZT amount in blood and remaining patches was quantified using LC-MS/MS 
method. We observed complete delivery of the drug within 24 hours with the drug 
concentrations peaking at 3 hours. Drug concentrations fell to baseline at around 15 
hours (Figure 8A). Delivery efficiency was calculated for all patches after delivery and 
was found to be 100% (Figure 8B). 
 
 
Figure 7. AZT loaded PVA hydrogel  





Figure 8. In vivo delivery of PVA-AZT hydrogels  
A. Lateral back skin of BALB/c mice was exposed to 10mJ laser treatment at 10% 
coverage followed by topical application of PVA-AZT hydrogel patches. Delivery 
kinetics were measured using LC-MS/MS. B. Patches were removed day 3 and 






In this study, we explored polymeric hydrogel-based drug delivery via AFL-generated 
skin MCs. pHEMA hydrogel elicited linear SRB release for 15 days (Figure 1A) and 
achieved a delivery efficiency of around 60% (Figure 1B) in in vitro Franz cell 
systems. However, it failed to elicit high-efficient delivery in vivo potentially due to 
the challenge to maintain a moisturized system for hydrogel-based deliveries. This can 
be supported by the fact that the hydrogel dried up within 1-2 days of application to 
mouse skin and delivery could not be continued. This can also be due to the difference 
in water content in pHEMA and PVA hydrogels. Once the contact lens hydrogel is 
applied to laser-ablated skin, only one face of the patch is in contact with the 
transepidermal water. This water is not taken up by the hydrogel system due to drying 
of the polymer matrix. Hence, it is hard to maintain an environment suitable for drug 
dissolution via aqueous skin MCs. 
We found high efficient delivery of SRB and AZT in vitro and in vivo for hydrogels 
formulated with high-molecular-weight PVA (Figures 4-7). More than 80% SRB was 
delivered in vitro at day 10 (Figure 4B). We further explored PVA hydrogel-based in 
vivo delivery of SRB at two loading levels (2.8mg and 6.9mg). Complete delivery of 
SRB at the two loading levels was achieved in 3 days (Figure 5, 6). The reason of such 
high delivery efficiency can be attributed to the water-rich hydrogel itself, which 
facilitates easier and faster diffusion of drugs through skin MCs. 
Lastly, we explored PVA hydrogel-based real drug AZT delivery via AFL-generated 
skin MCs in vivo. Serum AZT concentration peaked at 3 hours and returned to 




Chapter I, which peaked at 30 minutes and returned to baseline at 3 hours, hydrogel 
mediated delivery was able to extend the duration of delivery by 5 folds. We found 
almost complete delivery of AZT at the end of 24 hours (Figure 7B). In our previous 
oral AZT administration (Figure 3D, Manuscript I), we obtained an area under the 
curve (AUC) of 8,666 ng.h/ml at 0.32 mg dose. For AZT hydrogel delivery, AUC was 
calculated to be 119,868 ng.h/ml at 1.8 mg dose. We then compared the relative 
bioavailability of the two deliveries and found AFL-assisted hydrogel delivery 
increased AZT bioavailability by ~130% as compared to oral delivery. The PVA 
hydrogel could hold approximately 1.8 mg AZT and maintain its form when stored at 
4°C in sealed bags. For a 10 cm2 patch, almost 72 mg drug can be loaded for efficient 
delivery. Such a delivery capacity exceeds traditional patches, which contain a 
maximal drug dose of ~10 mg.  
To our knowledge, this is the first study to explore hydrogel-based drug delivery via 
laser-generated skin MCs. The safe laser technology and efficient delivery warrants 
further investigation for needle-free, painless transdermal drug and vaccine delivery. 
Conclusion 
In summary, we explored AFL-based hydrogels for small molecule drug delivery in 
murine models. PVA hydrogels were found as an ideal delivery platform for efficient 
and sustained delivery of SRB and AZT via laser-generated skin MCs. The convenient 
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